References
-
1.
Jadoul M, Albert JM, Akiba T, Akizawa T, Arab L, Bragg-Gresham JL, et al. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2006;70(7):1358-66. [PubMed ID: 16929251]. https://doi.org/10.1038/sj.ki.5001754.
-
2.
Hofbauer LC, Brueck CC, Singh SK, Dobnig H. Osteoporosis in patients with diabetes mellitus. J Bone Miner Res. 2007;22(9):1317-28. [PubMed ID: 17501667]. https://doi.org/10.1359/jbmr.070510.
-
3.
Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999;282(7):637-45. https://doi.org/10.1001/jama.282.7.637.
-
4.
Saito O, Saito T, Asakura S, Akimoto T, Inoue M, Ando Y, et al. Effects of Raloxifene on Bone Metabolism in Hemodialysis Patients With Type 2 Diabetes. Int J Endocrinol Metab. 2012;10(2):464-9. https://doi.org/10.5812/ijem.3794.
-
5.
Lasco A, Gaudio A, Morabito N, Previti M, Mileto A, Frisina N, et al. Effects of a long-term treatment with raloxifene on insulin sensitivity in postmenopausal women. Diabetologia. 2004;47(3):571-4. [PubMed ID: 14762655]. https://doi.org/10.1007/s00125-004-1328-4.